-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Under the resonance of factors such as the continuous release of favorable policies and capital increase, the domestic biopharmaceutical industry has developed very well
.
The industry predicts that by 2025, the market size of China's biopharmaceutical industry will exceed 800 billion yuan
.
At present, in order to undertake the good, pharmaceutical companies have begun to expand production
.
It is worth noting that, affected by this, the demand for upstream pharmaceutical equipment, especially biomedical equipment, is growing rapidly, and the entire pharmaceutical industry has ushered in a new round of opportunities, which has been reflected in the performance of many companies
.
The development of the biopharmaceutical industry continues to accelerate (Source: Pharmaceutical Network) Pharmaceutical companies have expanded production, and biomedical equipment companies have ushered in good news.
Profit and profit: RMB 71,000,000 – RMB 80,000,000, an increase of 121.
63%-149.
73% over the same period of the previous year
.
During the reporting period, the company's net profit attributable to shareholders of listed companies increased compared with the same period of the previous year, mainly because the sales revenue of the company's semiconductor business and biomedical business maintained steady growth
.
In addition, Tofflon has begun to lay out the bioengineering track in 2016.
In 2021, the company also acquired Qianchun Biology and invested in Saipu, and gradually expanded to the downstream consumables/devices field
.
From 2020 to 2021, the revenue of its bioengineering sector will increase by 220% and 305.
15%, respectively, and the proportion of revenue will reach 8.
27% and 21.
63%, respectively
.
In fact, China's biopharmaceutical industry is in an explosive stage
.
At present, a large number of enterprises are expanding their production capacity in order to meet the market demand
.
For example, not long ago, Sele Pharmaceutical announced the completion of nearly 100 million yuan in Series B financing.
It is reported that the raised funds will be mainly used to assist the research and development and clinical development of Sele Pharmaceutical, as well as the construction of new production bases
.
Therefore, as the main part of the production cost of biological drugs, it has driven the development of China's pharmaceutical machinery industry to a certain extent, and it is also expected to bring more market increments to pharmaceutical equipment companies
.
Biomedicine is one of the promising and promising strategic emerging industries.
At present, the relevant state departments have issued a number of documents such as the "14th Five-Year Plan for Pharmaceutical Industry Development" and the "14th Five-Year Plan for Bioeconomic Development".
, pointing out the direction for the future high-quality development of the biopharmaceutical industry
.
The industry predicts that with favorable policies, a large number of biomedical companies will usher in more opportunities, and the demand for biomedical equipment, especially high-end equipment, will continue to grow
.
Affected by this, the high-end pharmaceutical equipment market will usher in a new round of opportunities, and powerful leading pharmaceutical machine companies are expected to embrace the opportunity and speed up import substitution
.
Head pharmaceutical equipment is starting to expand production At present, in fact, many head pharmaceutical equipment companies have also begun to expand production in order to better meet market demand
.
For example, recently, the project of Chutian Changxing Precision Medical Equipment Intelligent Manufacturing Base was officially signed and settled in Ningxiang Economic and Technological Development Zone.
The project is invested, constructed and operated by Chutian Changxing Precision Manufacturing (Changsha) Co.
, Ltd.
Phased construction, focusing on the development of precision transmission components and industrial robots
.
It is reported that this project is another important project in the biomedicine and life science industry chain of Chutian Science and Technology.
Further efforts will be made in the construction of the biomedical and life science industry chain with complementary advantages and integrated development of large and medium-sized enterprises
.
In addition, Tofflon’s prospectus for the issuance of A shares to specific objects in 2022 shows that the total amount of funds raised by the issuance of stocks to specific objects this time does not exceed 3.
2 billion yuan (including this amount), which is planned to be used to invest in biological Pharmaceutical equipment industry trial production center project, Jiangsu biomedical equipment industrialization base project, Zhejiang Tofflon Biotechnology Co.
, Ltd.
life science industrialization base project and supplementary working capital
.
This is not Tofflon's second major expansion of production.
As early as May 2020, Tofflon announced that the company plans to invest 500 million yuan to build a biopharmaceutical system equipment industrialization project, of which 350 million yuan will be invested in the first phase.
It will be put into production in 3 years, and the production will be realized in 5 years, with an annual output value of more than 500 million yuan
.
Analysts believe that these leading pharmaceutical machine companies have invested heavily in new production capacity, which fully shows their determination to deploy in the field of biomedicine and try to stand out in the high-end market with production capacity and technology
.
However, it should be noted that with the expansion of production by leading companies, the competition before companies in the biopharmaceutical field may be more intense in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The industry predicts that by 2025, the market size of China's biopharmaceutical industry will exceed 800 billion yuan
.
At present, in order to undertake the good, pharmaceutical companies have begun to expand production
.
It is worth noting that, affected by this, the demand for upstream pharmaceutical equipment, especially biomedical equipment, is growing rapidly, and the entire pharmaceutical industry has ushered in a new round of opportunities, which has been reflected in the performance of many companies
.
The development of the biopharmaceutical industry continues to accelerate (Source: Pharmaceutical Network) Pharmaceutical companies have expanded production, and biomedical equipment companies have ushered in good news.
Profit and profit: RMB 71,000,000 – RMB 80,000,000, an increase of 121.
63%-149.
73% over the same period of the previous year
.
During the reporting period, the company's net profit attributable to shareholders of listed companies increased compared with the same period of the previous year, mainly because the sales revenue of the company's semiconductor business and biomedical business maintained steady growth
.
In addition, Tofflon has begun to lay out the bioengineering track in 2016.
In 2021, the company also acquired Qianchun Biology and invested in Saipu, and gradually expanded to the downstream consumables/devices field
.
From 2020 to 2021, the revenue of its bioengineering sector will increase by 220% and 305.
15%, respectively, and the proportion of revenue will reach 8.
27% and 21.
63%, respectively
.
In fact, China's biopharmaceutical industry is in an explosive stage
.
At present, a large number of enterprises are expanding their production capacity in order to meet the market demand
.
For example, not long ago, Sele Pharmaceutical announced the completion of nearly 100 million yuan in Series B financing.
It is reported that the raised funds will be mainly used to assist the research and development and clinical development of Sele Pharmaceutical, as well as the construction of new production bases
.
Therefore, as the main part of the production cost of biological drugs, it has driven the development of China's pharmaceutical machinery industry to a certain extent, and it is also expected to bring more market increments to pharmaceutical equipment companies
.
Biomedicine is one of the promising and promising strategic emerging industries.
At present, the relevant state departments have issued a number of documents such as the "14th Five-Year Plan for Pharmaceutical Industry Development" and the "14th Five-Year Plan for Bioeconomic Development".
, pointing out the direction for the future high-quality development of the biopharmaceutical industry
.
The industry predicts that with favorable policies, a large number of biomedical companies will usher in more opportunities, and the demand for biomedical equipment, especially high-end equipment, will continue to grow
.
Affected by this, the high-end pharmaceutical equipment market will usher in a new round of opportunities, and powerful leading pharmaceutical machine companies are expected to embrace the opportunity and speed up import substitution
.
Head pharmaceutical equipment is starting to expand production At present, in fact, many head pharmaceutical equipment companies have also begun to expand production in order to better meet market demand
.
For example, recently, the project of Chutian Changxing Precision Medical Equipment Intelligent Manufacturing Base was officially signed and settled in Ningxiang Economic and Technological Development Zone.
The project is invested, constructed and operated by Chutian Changxing Precision Manufacturing (Changsha) Co.
, Ltd.
Phased construction, focusing on the development of precision transmission components and industrial robots
.
It is reported that this project is another important project in the biomedicine and life science industry chain of Chutian Science and Technology.
Further efforts will be made in the construction of the biomedical and life science industry chain with complementary advantages and integrated development of large and medium-sized enterprises
.
In addition, Tofflon’s prospectus for the issuance of A shares to specific objects in 2022 shows that the total amount of funds raised by the issuance of stocks to specific objects this time does not exceed 3.
2 billion yuan (including this amount), which is planned to be used to invest in biological Pharmaceutical equipment industry trial production center project, Jiangsu biomedical equipment industrialization base project, Zhejiang Tofflon Biotechnology Co.
, Ltd.
life science industrialization base project and supplementary working capital
.
This is not Tofflon's second major expansion of production.
As early as May 2020, Tofflon announced that the company plans to invest 500 million yuan to build a biopharmaceutical system equipment industrialization project, of which 350 million yuan will be invested in the first phase.
It will be put into production in 3 years, and the production will be realized in 5 years, with an annual output value of more than 500 million yuan
.
Analysts believe that these leading pharmaceutical machine companies have invested heavily in new production capacity, which fully shows their determination to deploy in the field of biomedicine and try to stand out in the high-end market with production capacity and technology
.
However, it should be noted that with the expansion of production by leading companies, the competition before companies in the biopharmaceutical field may be more intense in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
